Expand ANIX Menu
ANIX MENU

ANIX Latest Press Releases

-- April 9, 2026 --

Anixa Biosciences to Participate in RedChip's Biotech Resurgence: Platforms and Pipelines of Today's Innovators Conference on April 16, 2026 PRNewswire 9:05 AM

-- April 7, 2026 --

Anixa Biosciences to Participate in Water Tower Research Insights Conference on April 14, 2026 PRNewswire 8:55 AM

-- April 6, 2026 --

Anixa Biosciences CEO Featured on Smart Money Circle Interview Highlighting Advances in Cancer Immunotherapy Programs PRNewswire 9:10 AM

-- April 1, 2026 --

Anixa Biosciences Advances Breast Cancer Vaccine Toward Phase 2 After Positive Phase 1 Results; Cytovance Selected for cGMP Manufacturing PRNewswire 8:50 AM

-- March 30, 2026 --

Anixa Biosciences Announces Presentation of its Ovarian Cancer CAR-T Therapy Clinical Trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer PRNewswire 9:05 AM

-- March 12, 2026 --

Anixa Biosciences Featured on Water Tower Research Healthcare Happenings Podcast PRNewswire 10:39 AM

-- March 9, 2026 --

Anixa Biosciences Receives Notice of Allowance from Korean Ministry of Intellectual Property (MOIP) for Patent Covering Breast Cancer Vaccine Technology PRNewswire 8:30 AM

-- March 2, 2026 --

Anixa Biosciences to Host 2026 Annual Meeting of Stockholders and Provide Corporate Update Highlighting Recent Clinical and Regulatory Progress PRNewswire 9:10 AM

-- February 23, 2026 --

Anixa Biosciences Announces Dr. Jose Conejo-Garcia will Keynote the South Carolina Clinical & Translational Research Institute 2026 Retreat PRNewswire 8:55 AM

-- February 9, 2026 --

Anixa Biosciences Reports Encouraging Patient Survival Observations in Ovarian Cancer CAR-T Trial; Achieves Regulatory Approval Enabling Major Dose Escalation PRNewswire 8:00 AM

-- February 2, 2026 --

Anixa Biosciences Secures United States Adopted Names Council Approval of Non-Proprietary Name for its CAR-T Therapy, a Key Step Toward Future Commercialization PRNewswire 9:00 AM

-- January 27, 2026 --

Anixa Biosciences Receives Notice of Allowance from Mexican Institute of Industrial Property (IMPI) for Patent Covering Breast Cancer Vaccine Technology PRNewswire 8:30 AM

-- December 15, 2025 --

Anixa Biosciences Announces Transfer of IND for Breast Cancer Vaccine from Cleveland Clinic PRNewswire 8:45 AM

-- December 11, 2025 --

Anixa Biosciences Announces Positive Phase 1 Data for Investigational Breast Cancer Vaccine; Primary Endpoints Were Met and Immune Response Observed in 74% of Participants PRNewswire 6:02 PM

-- December 10, 2025 --

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Monday, December 15, 2025 PRNewswire 9:00 AM

-- November 17, 2025 --

Anixa Biosciences Announces World Health Organization (WHO) Approval of International Non-Proprietary Name for its CAR-T Therapy, Marking a Key Milestone Toward Global Recognition and Future Commercialization PRNewswire 8:15 AM

-- November 12, 2025 --

Water Tower Research Issues Statement Regarding Technical Interruption During Anixa Biosciences Fireside Chat Globe Newswire 11:00 AM
Anixa Biosciences Awarded Key U.S. Patent Expanding Breast Cancer Vaccine IP Protection into 2040s PRNewswire 9:00 AM

-- November 10, 2025 --

Anixa Biosciences to Participate in Water Tower Research Fireside Chat on Tuesday, November 11, 2025 PRNewswire 10:30 AM
Market Data Delayed 15 Minutes